NICE backs Velcade, SGLT2 diabetes meds for new uses; Novartis chief keeps faith in performance pricing;

@FiercePharma: Sun Pharma said to be in talks to buy Intas for $2.3B. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: Bulgarian vet drug company Huvepharma picks up 3 plants from Zoetis for $40M. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio. More | Follow @CarlyHFierce

> U.K. cost-effectiveness watchdogs backed Johnson & Johnson's ($JNJ) Velcade in mantle cell lymphoma, and three SGLT2 diabetes drugs--J&J's Invokana, AstraZeneca's ($AZN) Forxiga and Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's Jardiance--as monotherapies in certain patients. Report

> Novartis ($NVS) CEO Joe Jimenez continues to back performance-based pricing for meds, saying that such models will have more effect on drug costs that legislation can. Report

> Sanofi ($SNY) submitted its insulin-plus-GLP-1 diabetes drug LixiLan to the FDA, hoping for an approval next year; one half of that med, the GLP-1 Lyxumia, is awaiting an FDA nod now. Release | More

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Boston Sci's Watchman more cost-effective than drugs in the long term. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI yesterday: Olympus played down early report of superbug infections linked to duodenoscope devices. Report | Follow @EmilyWFierce

@VarunSaxena2: UPDATED: Medical device tax suspended in $1.8T federal budget. Story | Follow @VarunSaxena2

> Italian orthopedic implant maker Lima trades hands from one investor to another. Story

> U.K. scientists roll out computer program for drug-resistant bacteria Dx. Report

> Theranos blows its top over WSJ reports on proprietary testing. Article

Biotech News

@FierceBiotech: Columbia U. scientists spotlight a promising proteasome approach in preventing Alzheimer's. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: I don't get to mention baseball much in my work. Today I get the Mets. More from FierceBiotechResearch | Follow @JohnCFierce

@DamianFierce: hashtag infinitesimal innovation. More from Forbes | Follow @DamianFierce

> Shire's Baxalta buyout looks more and more likely as year winds down. Report

> Sanofi takes an FDA shortcut with its diabetes combo, racing with Novo. Story

> AstraZeneca bags FDA OK on gout drug lesinurad as safety doubts linger. Article

Biotech Research News

> Moneyball's analytics wiz DePodesta joins Scripps' Big Data team. News

> Transatlantic research team spotlights promise of mTOR drugs for follicular lymphoma. Report

> An intriguing anti-aging drug target may also work on PTSD. Story

> Candidate Clinton calls for $2B in annual Alzheimer's R&D support. Item

> Columbia U. scientists spotlight a promising proteasome approach in preventing Alzheimer's. Article

Vaccines News

> In $171M deal, Bavarian Nordic and J&J's Janssen extend efforts to HPV. More

> GlaxoSmithKline launched new e-commerce platform for vaccines, pharma products. Story

> Vaxart initiates PhI trial of oral influenza B vaccine. Item

> European MERS vaccine effective in camels. Report

> Sanofi's dengue vaccine gets first Asian approval with more discussions underway. Article

Pharma Marketing News

> Going beyond smiling, happy patients: Is better creative on the pharma horizon? More

> Celgene buries the hatchet with India's Natco over generic Revlimid. Item

> Price and reputation are indubitably, inexorably intertwined. Report

> Outcome-based healthcare needs outcome-based marketing. Article

> Pharma marketers steer through changing tides. Story

And Finally... Public health officials are pushing for wider use of a Gilead Sciences ($GILD) drug to prevent HIV infection, but some AIDS groups continue to oppose it. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.